Stock-Based Payments (Details) - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-Based Compensation Expenses | | $ 31,000,000 | | $ 40,000,000 | $ 66,000,000 | | $ 80,000,000 |
Common Shares Available for Grant | | 20,000,000 | | | 20,000,000 | | |
Aggregate Maximum of Common Shares | | 20,000,000 | | | 20,000,000 | | |
Stock Options And SARs | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-based compensation expense related to stock options, SAR and ESPP grants | | $ 9,000,000 | | $ 15,000,000 | $ 19,000,000 | | $ 29,000,000 |
Unrecognized compensation expense | | $ 37,000,000 | | | $ 37,000,000 | | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | | | | 1 year 7 months 6 days | | |
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract] | | | | | | | |
Weighted Average Fair Value of Grants (price per share) | | | | | $ 20.73 | | $ 16.94 |
Expected Volatility (in hundredths) | | | | | 46.40% | | 42.10% |
Risk-Free Interest Rate (in hundredths) | | | | | 0.36% | | 0.93% |
Dividend Yield (in hundredths) | | | | | 2.87% | | 1.94% |
Expected Life (in years) | | | | | 5 years 2 months 12 days | | 5 years 1 month 6 days |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | | | | | | | |
Outstanding at January 1 (in shares) | | | | | 10,186,000 | | 9,395,000 |
Granted (in shares) | | | | | 14,000 | | 16,000 |
Exercised (1) (in shares) | [1] | | | | (239,000) | | (23,000) |
Forfeited (in shares) | | | | | (234,000) | | (389,000) |
Outstanding at June 30 (2) | [2] | 9,727,000 | | 8,999,000 | 9,727,000 | | 8,999,000 |
Stock Options and SARs Vested or Expected to Vest (3) (in shares) | [3] | 9,421,000 | | 8,670,000 | 9,421,000 | | 8,670,000 |
Stock Options and SARs Exercisable at March 31 (4) (in shares) | [4] | 6,023,000 | | 4,963,000 | 6,023,000 | | 4,963,000 |
Intrinsic Value of Stock Options/SARs Exercised | [1] | | | | $ 3,000,000 | | $ 400,000 |
Intrinsic Value of Stock Options/SARs Outstanding | [2] | $ 114,000,000 | | $ 100,000 | $ 114,000,000 | | $ 100,000 |
Weighted Average Remaining Contractual Life for Stock Options/SARs Outstanding (in years) | [2] | | | | 3 years 9 months 18 days | | 3 years 9 months 18 days |
Intrinsic Value of Stock Options/SARs Vested or Expected to Vest | [3] | 106,000,000 | | 100,000 | $ 106,000,000 | | $ 100,000 |
Weighted average remaining contractual life for stock options/SARs vested or expected to vest (in years) | [3] | | | | 3 years 9 months 18 days | | 3 years 10 months 24 days |
Aggregate Intrinsic Value for Exercisable Units | [4] | $ 16,000,000 | | $ 0 | $ 16,000,000 | | $ 0 |
Weighted average remaining contractual life for exercisable options/SARs (in years) | [4] | | | | 2 years 8 months 12 days | | 2 years 8 months 12 days |
Weighted Average Grant Price Stock Option and SARs [Rollforward] | | | | | | | |
Outstanding at January 1 (price per share) | | | | | $ 84.08 | | $ 94.53 |
Granted (price per share) | | | | | 64.97 | | 58.40 |
Exercised (1) (price per share) | [1] | | | | 69.85 | | 69.59 |
Forfeited (price per share) | | | | | 91.54 | | 91.39 |
Outstanding at June 30 (2) | [2] | $ 84.23 | | $ 94.66 | 84.23 | | 94.66 |
Vested or Expected to Vest (3) (price per share) | [3] | 84.91 | | 94.67 | 84.91 | | 94.67 |
Exercisable at June 30 (4) | [4] | $ 97.08 | | $ 94.61 | 97.08 | | 94.61 |
ESPP | | | | | | | |
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract] | | | | | | | |
Weighted Average Fair Value of Grants (price per share) | | | | | $ 14.69 | | $ 20.80 |
Expected Volatility (in hundredths) | | | | | 54.99% | | 35.24% |
Risk-Free Interest Rate (in hundredths) | | | | | 0.09% | | 1.56% |
Dividend Yield (in hundredths) | | | | | 3.41% | | 1.56% |
Expected Life (in years) | | | | | 6 months | | 6 months |
Restricted Stock And Restricted Stock Units | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Unrecognized compensation expense | | $ 133,000,000 | | | $ 133,000,000 | | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | | | | 1 year 3 months 18 days | | |
Share-Based Compensation Arrangement By Restricted Stock And Restricted Stock Units Compensation Cost | | $ 21,000,000 | | $ 24,000,000 | $ 45,000,000 | | $ 49,000,000 |
Restricted Stock/Restricted Stock Units and Performance Units [Roll Forward] | | | | | | | |
Outstanding at January 1 (in shares) | | | | | 4,742,000 | | 4,546,000 |
Granted (in shares) | | | | | 45,000 | | 67,000 |
Released (1) (in shares) | [5] | | | | (523,000) | | (304,000) |
Forfeited (in shares) | | | | | (47,000) | | (36,000) |
Outstanding at June 30 (3) | [6] | 4,217,000 | | 4,273,000 | 4,217,000 | | 4,273,000 |
Intrinsic value released during the year | [5] | | | | $ 38,000,000 | | $ 13,000,000 |
Aggregate intrinsic value of stock and units outstanding | [6] | $ 352,000,000 | | $ 217,000,000 | $ 352,000,000 | | $ 217,000,000 |
Weighted Average Grant Price Restricted Stock and Restricted Stock Units [Roll Forward] | | | | | | | |
Outstanding at January 1 (price per share) | | | | | $ 74.97 | | $ 90.16 |
Granted (price per share) | | | | | 72.56 | | 51.83 |
Released (2) (price per share) | [5] | | | | 87.61 | | 88.58 |
Forfeited (price per share) | | | | | 70.24 | | 90.61 |
Outstanding at June 30 (3) (price per share) | [6] | $ 73.43 | | $ 89.67 | $ 73.43 | | $ 89.67 |
Performance Unit | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-Based Compensation Expenses | | $ 1,000,000 | | $ 1,000,000 | $ 2,000,000 | | $ 2,000,000 |
Unrecognized compensation expense | | $ 6,000,000 | | | $ 6,000,000 | | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | | | | 1 year 8 months 12 days | | |
Restricted Stock/Restricted Stock Units and Performance Units [Roll Forward] | | | | | | | |
Outstanding at January 1 (in shares) | | | | | 613,000 | | 598,000 |
Granted (in shares) | | | | | 8,000 | | 0 |
Granted for Performance Multiple (1) | [7] | | | | 19,000 | | 66,000 |
Released (1) (in shares) | [8] | | | | (98,000) | | (121,000) |
Forfeited (in shares) | | | | | 0 | | 0 |
Outstanding at June 30 (3) | [9] | 542,000 | [10] | 543,000 | 542,000 | [10] | 543,000 |
Intrinsic value released during the year | | | | | $ 6,000,000 | [8] | $ 9,000,000 |
Aggregate intrinsic value of stock and units outstanding | [9] | $ 45,000,000 | | $ 28,000,000 | $ 45,000,000 | | $ 28,000,000 |
Weighted Average Grant Price Restricted Stock and Restricted Stock Units [Roll Forward] | | | | | | | |
Outstanding at January 1 (price per share) | | | | | $ 88.38 | | $ 103.91 |
Granted (price per share) | | | | | 55.69 | | 0 |
Granted for Performance Multiple (1) (in dollars per share) | [7] | | | | 113.81 | | 119.10 |
Released (2) (price per share) | [8] | | | | 113.81 | | 123.56 |
Forfeited (price per share) | | | | | 0 | | 0 |
Outstanding at June 30 (3) (price per share) | [9] | $ 84.23 | | $ 101.38 | $ 84.23 | | $ 101.38 |
Performance Units and Performance Stock Disclosures [Abstract] | | | | | | | |
Performance Period for Performance Units and Shares | | | | | 3 years | | |
Minimum Performance Multiple at the Completion of the Performance Period | | | | | 0.00% | | |
Maximum Performance Multiple at the Completion of the Performance Period | | | | | 200.00% | | |
Performance Multiple Applied at the Completion Period | [7] | | | | 125.00% | | 150.00% |
Minimum Performance Units and Stock Allowed to be Outstanding | [10] | | | | 76,785 | | |
Maximum Performance Units Allowed to be Outstanding | [10] | | | | 1,007,705 | | |
Lease and Well | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-Based Compensation Expenses | | $ 11,000,000 | | $ 15,000,000 | $ 25,000,000 | | $ 30,000,000 |
Gathering and Processing Costs | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-Based Compensation Expenses | | 1,000,000 | | 1,000,000 | 1,000,000 | | 1,000,000 |
Exploration Costs | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-Based Compensation Expenses | | 5,000,000 | | 7,000,000 | 11,000,000 | | 14,000,000 |
General and Administrative | | | | | | | |
Stock Options/SARs, Employee Stock Purchase Plan (ESPP), Restricted Stock and Restricted Stock Units and Performance Units Disclosures [Line Items] | | | | | | | |
Stock-Based Compensation Expenses | | $ 14,000,000 | | $ 17,000,000 | $ 29,000,000 | | $ 35,000,000 |
| |
[1] | The total intrinsic value of stock options/SARs exercised during the six months ended June 30, 2021 and 2020 was $3.0 million and $0.4 million, respectively. The intrinsic value is based upon the difference between the market price of EOG's common stock on the date of exercise and the exercise price of the stock options/SARs. | |
[2] | The total intrinsic value of stock options/SARs outstanding at June 30, 2021 and 2020 was $114 million and $0.1 million, respectively. At June 30, 2021 and 2020, the weighted average remaining contractual life was 3.8 years and 3.9 years, respectively. | |
[3] | The total intrinsic value of stock options/SARs vested or expected to vest at June 30, 2021 and 2020 was $106 million and $0.1 million, respectively. At June 30, 2021 and 2020, the weighted average remaining contractual life was 3.8 years and 3.9 years, respectively. | |
[4] | The total intrinsic value of stock options/SARs exercisable at June 30, 2021 and 2020 was $16 million and zero, respectively. At June 30, 2021 and 2020, the weighted average remaining contractual life was 2.7 years. | |
[5] | The total intrinsic value of restricted stock and restricted stock units released during the six months ended June 30, 2021 and 2020 was $38 million and $13 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the restricted stock and restricted stock units are released. | |
[6] | The total intrinsic value of restricted stock and restricted stock units outstanding at June 30, 2021 and 2020 was $352 million and $217 million, respectively. | |
[7] | Upon completion of the Performance Period for the performance units granted in 2017 and 2016, a performance multiple of 125% and 150%, respectively, was applied to each of the grants resulting in additional grants of performance units in February 2021 and February 2020, respectively. | |
[8] | The total intrinsic value of performance units released during the six months ended June 30, 2021 and 2020 was $6 million and $9 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the performance units are released. | |
[9] | The total intrinsic value of performance units outstanding at June 30, 2021 and 2020 was approximately $45 million and $28 million, respectively. | |
[10] | Upon the application of the relevant performance multiple at the completion of each of the remaining Performance Periods, a minimum of 76,785 and a maximum of 1,007,705 performance units could be outstanding. | |